Bausch Health Companies Inc. (BHC)
| Market Cap | 2.36B +4.4% |
| Revenue (ttm) | 10.85B +10.1% |
| Net Income | -1.10B |
| EPS | -2.95 |
| Shares Out | 373.99M |
| PE Ratio | n/a |
| Forward PE | 1.43 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,305,835 |
| Open | 5.95 |
| Previous Close | 5.89 |
| Day's Range | 5.95 - 6.35 |
| 52-Week Range | 4.33 - 8.00 |
| Beta | 0.37 |
| Analysts | Hold |
| Price Target | 7.50 (+18.86%) |
| Earnings Date | Oct 28, 2026 |
About BHC
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The company develops, manufactures, and markets products primarily in the therapeutic areas of gastroenterology, hepatology, neurology and dermatology, generic and branded generic pharmaceuticals, dentistry products, over-the-counter products, aesthetic medical devices, and eye health. The company sells its products in the United States... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for BHC stock is "Hold." The 12-month stock price target is $7.5, which is an increase of 18.86% from the latest price.
News
Bausch Health reports results from study of pathway for cirrhosis management
Bausch Health (BHC) Companies and its gastroenterology business, Salix Pharmaceuticals, announced results from a multicenter pilot study evaluating a standardized clinical pathway for cirrhosis manage...
Six-Month Pilot Study Demonstrates Improved Guideline Adherence Following Implementation of Standardized Cirrhosis Clinical Pathway
LAVAL, QC, Oct. 12, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), announced results from a multicenter ...
Bausch + Lomb names Thomas Appio as interim CEO
Bausch + Lomb (BLCO) and its parent company, Bausch Health (BHC), announced that Bausch + Lomb Board of Directors Chairman Thomas Appio has been appointed interim chief executive officer, effective…
Bausch + Lomb, Bausch Health expect to raise FY26 adjusted EBITDA, ex IPR&D
Based on preliminary third-quarter results, Bausch + Lomb (BLCO) and Bausch Health (BHC) currently expect to raise full-year 2026 adjusted EBITDA excluding Acquired IPR&D guidance. The companies are c...
Bausch + Lomb and Bausch Health Announce Appointment of Thomas J. Appio as Interim Bausch + Lomb CEO, Expect to Raise Full-Year 2026 Guidance
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company, and its parent company, Bausch Health Companies Inc. (NYSE/TSX: BHC), today announce...
Bausch Health to Announce Third Quarter 2026 Results on October 28, 2026
LAVAL, QC, Oct. 6, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release third quarter 2026 financial results after market close on Wednesday, October 28, 2026. Bausch Hea...
Bausch Health and YUN expand to Mexico and additional EMEA Markets
Bausch Health (BHC) and YUN, a Belgian company dealing in probiotherapeutical skincare products, announced the continued expansion of their strategic collaboration in Mexico and across additional EMEA...
Bausch Health and YUN Announce Expansion to Mexico and Across Additional EMEA Markets
Collaboration expands access to science-led, microbiome-friendly skincare solutions in Mexico and across new markets in EMEA, including launches in the Czech Republic, Slovakia, Ukraine, Bulgaria and ...
Bausch Health announces availability of Solta Medical’s Fraxel FTX in Australia
Bausch Health (BHC) Companies announced the availability of Fraxel FTX in Australia, expanding access to its latest skin resurfacing technology to Australian health care practitioners beginning Septem...
Bausch Health's Ortho Dermatologics Announces the 2026 Aspire Higher Scholarship Winners
This year's Aspire Higher scholarships are awarded to six students who have been affected by dermatologic conditions. LAVAL, QC, Aug. 27, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(T...
Bausch + Lomb Advancing Two First-in-Class Eye Health Therapies Based on Trial Results
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that two of it...
Bausch Health Announces 2026 Gastrointestinal Health Scholars Program Winners
For the Seventh Consecutive Year, 10 Students with Gastrointestinal Disease Will Each Receive a $10,000 Scholarship LAVAL, QC, Aug. 17, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE: BHC)(T...
Bausch Health put volume heavy and directionally bearish
Bearish flow noted in Bausch Health (BHC) with 1,646 puts trading, or 1.8x expected. Most active are Dec-28 10 puts and Aug-26 5.5 puts, with total volume in those strikes…
Bausch Health CEO Thomas J. Appio Joins Bausch + Lomb Board
LAVAL, QC, Aug. 6, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC) ("Bausch Health" or the "Company"), today announced that its CEO, Thomas J. Appio, has been appointed to the ...
Bausch Health Companies Earnings Call Transcript: Q2 2026
Q2 saw record revenue and adjusted EBITDA growth, with all segments contributing and strong cash flow reducing net debt. Guidance for 2026 was raised across all metrics, though H2 faces headwinds from inventory accruals, loss of exclusivity, and Medicaid/340B erosion.
Bausch Health Companies Earnings release: Q2 2026
Bausch Health Companies released its Q2 2026 earnings on July 29, 2026, summarizing the period's financial results.
Bausch Health Companies Slides: Q2 2026
Bausch Health Companies has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 29, 2026.
Bausch Health Companies Quarterly report: Q2 2026
Bausch Health Companies has published its Q2 2026 quarterly earnings report on July 29, 2026.
Bausch Health reports Q2 non-GAAP EPS $1.26, consensus $1.01
Reports Q2 revenue $2.85B, consensus $2.66B. “Q2 marks our thirteenth consecutive quarter of year-over-year growth in Revenue and Adjusted EBITDA for Bausch Health (BHC), excluding Bausch + Lomb, refl...
BAUSCH HEALTH ANNOUNCES SECOND QUARTER 2026 RESULTS, RAISES GUIDANCE
Second Quarter Consolidated Revenues of $2.85 billion, up 13% on a Reported basis and 11% on an Organic (non-GAAP)1 basis over the prior year period GAAP Net Income Attributable to Bausch Health of $2...
Bausch to stop glaucoma eye drop development after trial miss
Bausch + Lomb said on Thursday its glaucoma eye drop had missed the main goal in a mid-stage trial of replicating visual function improvements observed in a smaller study.
Bausch Health to Announce Second Quarter 2026 Results on July 29, 2026
LAVAL, QC, July 7, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release second quarter 2026 financial results after market close on Wednesday, July 29, 2026. Bausch Healt...
Michael Goettler Resigns from Bausch Health's Board of Directors
LAVAL, QC, July 1, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that Michael Goettler has resigned from its Board of Directors, effective June 30, 2026, in con...
Bausch Health's Aesthetic Business, Solta Medical, Earns Prestigious Trademark Certification of Thermage® in China
Thermage ® , a pioneer in non-invasive skin tightening, was awarded the AAA Well-Known Trademark Certification, the highest recognition in China's domestic trademark evaluation system. LAVAL, QC, May...
Bausch Health Companies Transcript: RBC Capital Markets Global Healthcare Conference 2026
Management highlighted sustained growth across key franchises, strong execution in China and Solta, and a focus on maximizing cash flow through 2027. The company is preparing for post-XIFAXAN transition, managing legal risks, and considering options to monetize its BLCO stake.